Baseline patient characteristics for the overall cohort and according to the consolidation arm
| Characteristics . | Overall . | Consolidation arm . | ||||
|---|---|---|---|---|---|---|
| 12 cycles venetoclax . | MRD-guided venetoclax . | |||||
| No. . | % . | No. . | % . | No. . | % . | |
| Total patients | 67 | 32 | 30 | |||
| Age | ||||||
| Median (IQR) | 71 (68-75) | 72 (69-75) | 71 (68-74) | |||
| 18-70 | 21 | 31 | 9 | 28 | 12 | 40 |
| >70 | 46 | 69 | 23 | 72 | 18 | 60 |
| Sex | ||||||
| Male | 47 | 70 | 24 | 75 | 20 | 67 |
| Female | 27 | 30 | 8 | 25 | 10 | 33 |
| ECOG performance status | ||||||
| 0 | 35 | 52 | 17 | 53 | 14 | 47 |
| 1 | 29 | 43 | 14 | 44 | 14 | 47 |
| 2 | 3 | 5 | 1 | 3 | 2 | 7 |
| Cumulative illness rating scale | ||||||
| Median (IQR) | 3 (1-5) | 3 (1-5) | 3 (1-5) | |||
| ≥7 | 13 | 20 | 6 | 19 | 6 | 20 |
| Binet stage | ||||||
| A | 9 | 13 | 6 | 19 | 3 | 10 |
| B | 26 | 39 | 14 | 44 | 11 | 37 |
| C | 32 | 48 | 12 | 38 | 16 | 53 |
| IGHV mutational status | ||||||
| Mutated | 26 | 39 | 13 | 41 | 11 | 37 |
| Unmutated | 33 | 49 | 17 | 53 | 14 | 47 |
| Unknown | 8 | 12 | 2 | 6 | 5 | 17 |
| TP53 aberrations | 9 | 13 | 5 | 16 | 4 | 13 |
| Genomic complexity∗ | ||||||
| None | 52 | 78 | 25 | 78 | 23 | 77 |
| Low | 10 | 15 | 5 | 16 | 5 | 17 |
| High | 5 | 7 | 2 | 6 | 2 | 7 |
| Hemoglobulin concentration, g/dL | ||||||
| Median (IQR) | 11 (10-13) | 12 (10-13) | 11 (10-13) | |||
| Platelet count, ×109cells per L | ||||||
| Median (IQR) | 134 (91-212) | 143 (109-210) | 111 (79-220) | |||
| White blood cell count, ×109cells per L | ||||||
| Median (IQR) | 110 (65-217) | 82 (55-175) | 79 (9-159) | |||
| Lymphocyte count, ×109cells per L | ||||||
| Median (IQR) | 94 (55-175) | 95 (62-160) | 82 (55-175) | |||
| β2 microglobin concentration, mg/dL | ||||||
| Median (IQR) | 4 (3-5) | 4 (4-5) | 4 (3-6) | |||
| Creatinine clearance, mL/min | ||||||
| Median (IQR) | 73 (60-83) | 71 (57-79) | 73 (65-87) | |||
| <70 | 29 | 43 | 15 | 47 | 12 | 40 |
| CLL-IPI risk group | ||||||
| Low risk | 2 | 3 | 0 | 0 | 2 | 7 |
| Intermediate risk | 10 | 15 | 8 | 25 | 2 | 7 |
| High risk | 39 | 58 | 18 | 56 | 18 | 60 |
| Very high risk | 9 | 13 | 5 | 16 | 4 | 13 |
| Unknown | 7 | 10 | 1 | 3 | 4 | 13 |
| Follow-up time, mo | ||||||
| Median (IQR) | 44 (38-51) | 46 (38-52) | 44 (39-50) | |||
| Characteristics . | Overall . | Consolidation arm . | ||||
|---|---|---|---|---|---|---|
| 12 cycles venetoclax . | MRD-guided venetoclax . | |||||
| No. . | % . | No. . | % . | No. . | % . | |
| Total patients | 67 | 32 | 30 | |||
| Age | ||||||
| Median (IQR) | 71 (68-75) | 72 (69-75) | 71 (68-74) | |||
| 18-70 | 21 | 31 | 9 | 28 | 12 | 40 |
| >70 | 46 | 69 | 23 | 72 | 18 | 60 |
| Sex | ||||||
| Male | 47 | 70 | 24 | 75 | 20 | 67 |
| Female | 27 | 30 | 8 | 25 | 10 | 33 |
| ECOG performance status | ||||||
| 0 | 35 | 52 | 17 | 53 | 14 | 47 |
| 1 | 29 | 43 | 14 | 44 | 14 | 47 |
| 2 | 3 | 5 | 1 | 3 | 2 | 7 |
| Cumulative illness rating scale | ||||||
| Median (IQR) | 3 (1-5) | 3 (1-5) | 3 (1-5) | |||
| ≥7 | 13 | 20 | 6 | 19 | 6 | 20 |
| Binet stage | ||||||
| A | 9 | 13 | 6 | 19 | 3 | 10 |
| B | 26 | 39 | 14 | 44 | 11 | 37 |
| C | 32 | 48 | 12 | 38 | 16 | 53 |
| IGHV mutational status | ||||||
| Mutated | 26 | 39 | 13 | 41 | 11 | 37 |
| Unmutated | 33 | 49 | 17 | 53 | 14 | 47 |
| Unknown | 8 | 12 | 2 | 6 | 5 | 17 |
| TP53 aberrations | 9 | 13 | 5 | 16 | 4 | 13 |
| Genomic complexity∗ | ||||||
| None | 52 | 78 | 25 | 78 | 23 | 77 |
| Low | 10 | 15 | 5 | 16 | 5 | 17 |
| High | 5 | 7 | 2 | 6 | 2 | 7 |
| Hemoglobulin concentration, g/dL | ||||||
| Median (IQR) | 11 (10-13) | 12 (10-13) | 11 (10-13) | |||
| Platelet count, ×109cells per L | ||||||
| Median (IQR) | 134 (91-212) | 143 (109-210) | 111 (79-220) | |||
| White blood cell count, ×109cells per L | ||||||
| Median (IQR) | 110 (65-217) | 82 (55-175) | 79 (9-159) | |||
| Lymphocyte count, ×109cells per L | ||||||
| Median (IQR) | 94 (55-175) | 95 (62-160) | 82 (55-175) | |||
| β2 microglobin concentration, mg/dL | ||||||
| Median (IQR) | 4 (3-5) | 4 (4-5) | 4 (3-6) | |||
| Creatinine clearance, mL/min | ||||||
| Median (IQR) | 73 (60-83) | 71 (57-79) | 73 (65-87) | |||
| <70 | 29 | 43 | 15 | 47 | 12 | 40 |
| CLL-IPI risk group | ||||||
| Low risk | 2 | 3 | 0 | 0 | 2 | 7 |
| Intermediate risk | 10 | 15 | 8 | 25 | 2 | 7 |
| High risk | 39 | 58 | 18 | 56 | 18 | 60 |
| Very high risk | 9 | 13 | 5 | 16 | 4 | 13 |
| Unknown | 7 | 10 | 1 | 3 | 4 | 13 |
| Follow-up time, mo | ||||||
| Median (IQR) | 44 (38-51) | 46 (38-52) | 44 (39-50) | |||
CLL-IPI, CLL International Prognostic Index; IGHV, immunoglobulin heavy chain variable.
Genomic complexity was defined as none in case of 0 or 2 copy number aberrations, low for 3 or 4 copy number aberrations, and high for ≥5 copy number aberrations.